Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cree, B. A.C.
Right arrow Articles by Genain, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cree, B. A.C.
Right arrow Articles by Genain, C.
Related Collections
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow All Demyelinating disease (CNS)
Right arrow Devic's syndrome
NEUROLOGY 2005;64:1270-1272
© 2005 American Academy of Neurology


Brief Communications

An open label study of the effects of rituximab in neuromyelitis optica

B. A.C. Cree, MD, PhD, MCR, S. Lamb, RN, K. Morgan, A. Chen, MD, E. Waubant, MD and C. Genain, MD

From University of California, San Francisco.

Address correspondence and reprint requests to Dr. Bruce A.C. Cree, Multiple Sclerosis Center at UCSF, 350 Parnassus Ave., Suite 908, San Francisco, CA 94117; e-mail: bcree{at}itsa.ucsf.edu

Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight patients were relapse free and median attack rate declined from 2.6 attacks/patient/year to 0 attacks/patient/year (p = 0.0078). Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013).


Bruce Cree’s contribution was supported in part by the Sylvia Lawry postdoctoral fellowship grant from the National Multiple Sclerosis Society.

Received December 30, 2004. Accepted in final form January 30, 2005.




This article has been cited by other articles:


Home page
PediatricsHome page
T. E. Lotze, J. L. Northrop, G. J. Hutton, B. Ross, J. S. Schiffman, and J. V. Hunter
Spectrum of Pediatric Neuromyelitis Optica
Pediatrics, October 6, 2008; (2008) peds.2007-2758v1.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S Jarius, D Franciotta, R Bergamaschi, S Rauer, K P Wandinger, H F Petereit, M Maurer, H Tumani, A Vincent, P Eichhorn, et al.
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica
J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1134 - 1136.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
A. Jacob, B. G. Weinshenker, I. Violich, N. McLinskey, L. Krupp, R. J. Fox, D. M. Wingerchuk, M. Boggild, C. S. Constantinescu, A. Miller, et al.
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
Arch Neurol, September 8, 2008; (2008) 65.11.noc80069.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. C. Novak, A. E. Lovett-Racke, and M. K. Racke
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol, September 1, 2008; 65(9): 1162 - 1165.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. McKeon, V. A. Lennon, T. Lotze, S. Tenenbaum, J. M. Ness, M. Rensel, N. L. Kuntz, J. P. Fryer, H. Homburger, J. Hunter, et al.
CNS aquaporin-4 autoimmunity in children
Neurology, July 8, 2008; 71(2): 93 - 100.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
R. A. Linker and B. C. Kieseier
Review: Innovative monoclonal antibody therapies in multiple sclerosis
Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 33 - 42.
[Abstract] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
T. Okamoto, M. Ogawa, Youwei Lin, M. Murata, S. Miyake, and T. Yamamura
Review: Treatment of neuromyelitis optica: Current debate
Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 43 - 52.
[Abstract] [PDF]


Home page
Arch NeurolHome page
P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al.
Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis
Arch Neurol, July 1, 2008; 65(7): 913 - 919.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. de Seze, F. Blanc, L. Jeanjean, H. Zephir, P. Labauge, M. Bouyon, L. Ballonzoli, G. Castelnovo, M. Fleury, S. Defoort, et al.
Optical Coherence Tomography in Neuromyelitis Optica
Arch Neurol, July 1, 2008; 65(7): 920 - 923.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
E Moreh, I Gartsman, D Karussis, D Rund, N Hiller, and Z Meiner
Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment
Multiple Sclerosis, July 1, 2008; 14(6): 860 - 861.
[PDF]


Home page
NeurologyHome page
M. C. Dalakas
Invited Article: Inhibition of B cell functions: Implications for neurology
Neurology, June 3, 2008; 70(23): 2252 - 2260.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al.
Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Brain, June 1, 2008; 131(6): 1455 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. J. Pittock and V. A. Lennon
Aquaporin-4 Autoantibodies in a Paraneoplastic Context
Arch Neurol, May 1, 2008; 65(5): 629 - 632.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
L. R Mehta, M. K Samuelsson, A. K Kleiner, A. D Goodman, J. H Anolik, R J. Looney, and S. R Schwid
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
Multiple Sclerosis, April 1, 2008; 14(3): 425 - 427.
[Abstract] [PDF]


Home page
Mult SclerHome page
R. A Wilcox, J. Burrow, M. Slee, J. Craig, and D. Thyagarajan
Neuromyelitis optica (Devic's disease) in a patient with syphilis
Multiple Sclerosis, March 1, 2008; 14(2): 268 - 271.
[Abstract] [PDF]


Home page
NeurologyHome page
M. Levy, J. Birnbaum, and D. Kerr
Finding NMO: Neuromyelitis optica in children
Neurology, January 29, 2008; 70(5): 334 - 335.
[Full Text] [PDF]


Home page
Arch NeurolHome page
S. J. Pittock, V. A. Lennon, J. de Seze, P. Vermersch, H. A. Homburger, D. M. Wingerchuk, C. F. Lucchinetti, H. Zephir, K. Moder, and B. G. Weinshenker
Neuromyelitis Optica and Non Organ-Specific Autoimmunity
Arch Neurol, January 1, 2008; 65(1): 78 - 83.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
F. Blanc, H. Zephir, C. Lebrun, P. Labauge, G. Castelnovo, M. Fleury, F. Sellal, C. Tranchant, K. Dujardin, P. Vermersch, et al.
Cognitive Functions in Neuromyelitis Optica
Arch Neurol, January 1, 2008; 65(1): 84 - 88.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
C. C. Glisson and S. L. Galetta
Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis?
Arch Ophthalmol, January 1, 2008; 126(1): 128 - 129.
[Full Text] [PDF]


Home page
NeurologyHome page
S. R. Hinson, S. J. Pittock, C. F. Lucchinetti, S. F. Roemer, J. P. Fryer, T. J. Kryzer, and V. A. Lennon
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica
Neurology, December 11, 2007; 69(24): 2221 - 2231.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
C. S. Yu, C. Z. Zhu, K. C. Li, Y. Xuan, W. Qin, H. Sun, and P. Chan
Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum
Radiology, July 1, 2007; 244(1): 249 - 256.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
E. M. Frohman and D. Kerr
Is Neuromyelitis Optica Distinct From Multiple Sclerosis?: Something for "Lumpers" and "Splitters"
Arch Neurol, June 1, 2007; 64(6): 903 - 905.
[Full Text] [PDF]


Home page
Mult SclerHome page
G.J.D. Hengstman, P. Wesseling, C.W.G.M. Frenken, and P.J.H. Jongen
Neuromyelitis optica with clinical and histopathological involvement of the brain
Multiple Sclerosis, June 1, 2007; 13(5): 679 - 682.
[Abstract] [PDF]


Home page
J. Immunol.Home page
M. Duddy, M. Niino, F. Adatia, S. Hebert, M. Freedman, H. Atkins, H. J. Kim, and A. Bar-Or
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
J. Immunol., May 15, 2007; 178(10): 6092 - 6099.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group
Treatment of pediatric multiple sclerosis and variants
Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
B. A. Choudry and J. W. Chan
An Update on Monoclonal Antibody Therapies in Multiple Sclerosis
Journal of Pharmacy Practice, April 1, 2007; 20(2): 167 - 180.
[Abstract] [PDF]


Home page
Mult SclerHome page
C Papeix, J-S Vidal, J de Seze, C Pierrot-Deseilligny, A Tourbah, B Stankoff, C Lebrun, T Moreau, P Vermersch, B Fontaine, et al.
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
Multiple Sclerosis, March 1, 2007; 13(2): 256 - 259.
[Abstract] [PDF]


Home page
Mult SclerHome page
T Fukazawa and S Kikuchi
A three-dimensional approach for understanding the spectrum of idiopathic inflammatory demyelinating disorders: importance of the 'attack-related severity' axis
Multiple Sclerosis, March 1, 2007; 13(2): 199 - 207.
[Abstract] [PDF]


Home page
Arch NeurolHome page
T. F. Scott, S. L. Kassab, and S. J. Pittock
Neuromyelitis optica IgG status in acute partial transverse myelitis.
Arch Neurol, October 1, 2006; 63(10): 1398 - 1400.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
P. H. Lalive, T. Menge, I. Barman, B. A. Cree, and C. P. Genain
Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.
Neurology, July 11, 2006; 67(1): 176 - 177.
[Full Text] [PDF]


Home page
Arch NeurolHome page
B. Weinstock-Guttman, M. Ramanathan, N. Lincoff, S. Q. Napoli, J. Sharma, J. Feichter, and R. Bakshi
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (devic disease).
Arch Neurol, July 1, 2006; 63(7): 957 - 963.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. J. Pittock, B. G. Weinshenker, C. F. Lucchinetti, D. M. Wingerchuk, J. R. Corboy, and V. A. Lennon
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.
Arch Neurol, July 1, 2006; 63(7): 964 - 968.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. A. Kerr
The lumping and splitting of inflammatory CNS diseases
Neurology, May 23, 2006; 66(10): 1466 - 1467.
[Full Text] [PDF]


Home page
NeurologyHome page
D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker
Revised diagnostic criteria for neuromyelitis optica
Neurology, May 23, 2006; 66(10): 1485 - 1489.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. J. Pittock, V. A. Lennon, K. Krecke, D. M. Wingerchuk, C. F. Lucchinetti, and B. G. Weinshenker
Brain abnormalities in neuromyelitis optica.
Arch Neurol, March 1, 2006; 63(3): 390 - 396.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.